NDA 020955 · Sanofi Aventis US
Ferrlecit
Sodium Ferric Gluconate Complex · Injection · Parenteral Iron Replacement
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Mar 16, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Feb 18, 1999
Approved uses
3
Original approval plus efficacy supplements
Registered trials
12
3 Phase 3, 0 recruiting
FAERS reports
2,174
1,765 serious, 449 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 7, 2025.
Ferrlecit is indicated for the treatment of iron deficiency anemia in adult patients and in pediatric patients age 6 years and older with chronic kidney disease receiving hemodialysis who are receiving supplemental epoetin therapy. Ferrlecit is an iron replacement product for treatment of iron deficiency anemia in adult patients and in pediatric patients age 6 years and older with chronic kidney disease receiving hemodialysis who are receiving supplemental epoetin therapy. ( 1 )
Mechanism: Ferrlecit is used to replete the body content of iron. Iron is critical for normal hemoglobin synthesis to maintain oxygen transport. Additionally, iron is necessary for metabolism and various enzymatic processes.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 13, 2004 Supplement 6 · Efficacy · priority review LabelLetterPediatric Medical Review
- Feb 2, 2001 Supplement 3 · Efficacy · priority review ReviewLetterLabel
- Feb 18, 1999 Original approval · Type 1 - New Molecular Entity · priority review ReviewLetterLabel
1 products under this application
- FERRLECIT · SODIUM FERRIC GLUCONATE COMPLEX EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML) · INJECTABLE, INJECTION · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Ferric Gluconate Complex" as an intervention, any sponsor and status, largest first.
- Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency AnemiaPivotal-lookingCompleted
American Regent, Inc.Industry
NCT00704353 · 735 participants · Start Jun 2008 · Primary completion Jul 2009
Drug: Ferric Carboxymaltose; Standard Medical Care (SMC) · For: Anemia
Sites: Norristown, Pennsylvania
- Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With CancerPivotal-lookingCompleted
Mayo ClinicAcademic, hospital or other
NCT00661999 · 502 participants · Start Jan 2006 · Primary completion Mar 2009
Drug: darbepoetin alfa; sodium ferric gluconate complex in sucrose · For: Anemia; Leukemia; Lymphoma and 4 more
Sites: Scottsdale, Arizona; Rochester, Minnesota
- IV Sodium Ferric Gluconate Complex in Patients Undergoing TAVIPivotal-lookingStatus unknown
Rambam Health Care CampusAcademic, hospital or other
NCT04797832 · 200 participants (planned) · Start Oct 18, 2020 · Primary completion Oct 31, 2024
Drug: IV Sodium Ferric Gluconate Complex · For: Iron Deficiency Anemia Due to Blood Loss; Aortic Stenosis
Sites: Haifa, Israel
- 2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.Pivotal-lookingCompleted
Watson PharmaceuticalsIndustry
NCT00223977 · 146 participants · Start Dec 2003 · Primary completion Nov 2004
Drug: Sodium Ferric Gluconate Complex; Sodium Ferric Gluconate Complex and 1 more · For: Iron Deficiency Anemia
Sites: Birmingham, Alabama; Mesa, Arizona; Los Angeles, California · 43 sites in all
- Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) PatientsCompleted
Watson PharmaceuticalsIndustry
NCT00224055 · 89 participants · Start Apr 2003 · Primary completion Sep 2004
Drug: Sodium Ferric Gluconate Complex in Sucrose Injection; Ferrous sulfate tablets · For: Anemia, Iron-Deficiency; Kidney Failure, Chronic
Sites: Tucson, Arizona; Los Angeles, California; Palo Alto, California · 24 sites in all
Watson PharmaceuticalsIndustry
NCT00534144 · 74 participants · Start Sep 2007 · Primary completion Nov 2008
Drug: iron sucrose injection, USP; sodium ferric gluconate complex in sucrose injection · For: Kidney Failure, Chronic; Anemia, Iron-Deficiency
Sites: Phoenix, Arizona; Alhambra, California; Bell Gardens, California · 13 sites in all
Kyntra BioIndustry
NCT01414075 · 60 participants · Start Jul 21, 2011 · Primary completion Jan 10, 2013
Drug: Roxadustat; Oral Iron and 1 more · For: Dialysis; Anemia
Sites: Northridge, California; Yuba City, California; Detroit, Michigan · 7 sites in all
Watson PharmaceuticalsIndustry
NCT00223964 · 59 participants · Start Jun 2003 · Primary completion Oct 2003
Drug: Ferrlecit (sodium ferric gluconate complex in sucrose injection) · For: Anemia
Sites: Birmingham, Alabama; Los Angeles, California; San Diego, California · 24 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea519
- vomiting463
- abdominal pain415
- dyspnoea397
- sepsis301
- general physical health deterioration293
- abdominal distension278
- off label use277
- hyponatraemia268
- ascites267
- multiple organ dysfunction syndrome265
- appendicitis263
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 61 |
| 2005 | 55 |
| 2006 | 71 |
| 2007 | 48 |
| 2008 | 57 |
| 2009 | 97 |
| 2010 | 73 |
| 2011 | 82 |
| 2012 | 76 |
| 2013 | 70 |
| 2014 | 81 |
| 2015 | 83 |
| 2016 | 67 |
| 2017 | 68 |
| 2018 | 48 |
| 2019 | 93 |
| 2020 | 128 |
| 2021 | 174 |
| 2022 | 120 |
| 2023 | 175 |
| 2024 | 218 |
| 2025 | 138 |
| 2026 | 91 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Ferrlecit* (Sodium Ferric Gluconat/Sucrose*) · HCPCS J2916
2024 spending
$250K
Beneficiaries
2,233
12,783 claims
Per beneficiary
$112
2024 ASP limit $2.22 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $295,322 |
| 2021 | $259,492 |
| 2022 | $229,902 |
| 2023 | $251,052 |
| 2024 | $250,133 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Sodium ferric gluconate complex in haemodialysis patients: a prospective evaluation of long-term safety.
Michael B, Coyne DW, Folkert VW, et al. · Nephrol Dial Transplant 2004 · Clinical Trial, Multicenter Study
- Sodium ferric gluconate complex maintenance therapy in children on hemodialysis.
Warady BA, Zobrist RH, Finan E · Pediatr Nephrol 2006 · Clinical Trial, Multicenter Study
- Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran.
Michael B, Coyne DW, Fishbane S, et al. · Kidney Int 2002 · Clinical Trial, Clinical Trial, Phase IV
- Single-dose pharmacokinetics of sodium ferric gluconate complex in iron-deficient subjects.
Seligman PA, Dahl NV, Strobos J, et al. · Pharmacotherapy 2004 · Clinical Trial, Randomized Controlled Trial
- Sodium ferric gluconate complex therapy in anemic children on hemodialysis.
Warady BA, Zobrist RH, Wu J, et al. · Pediatr Nephrol 2005 · Clinical Trial, Multicenter Study
- Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients.
Coyne DW, Adkinson NF, Nissenson AR, et al. · Kidney Int 2003 · Clinical Trial, Multicenter Study
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.